Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study

摘要

We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29 center dot 8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49 center dot 3% (75/152) and microbiologically defined infections (MDI) were 50 center dot 7% (77/152). Among 250 patients treated with ibrutinib, 28 center dot 8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66 center dot 7% (34/51), viral 19 center dot 6% (10/51) and invasive fungal diseases (IFD) 13 center dot 7% (7/51). Among the 112 patients treated with idelalisib, 32 center dot 1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54 center dot 2% (26/48). Bacterial infections were 34 center dot 6% (9/26), viral 61 center dot 5% (16/26) and IFD 3 center dot 8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66 center dot 7% vs. 34 center dot 6%;P= 0 center dot 007), while viral infections were most frequent in idelalisib (61 center dot 5% vs. 19 center dot 6%;P< 0 center dot 001). Although a higher rate of IFD was observed in patients treated with ibrutinib, the difference was not statistically significant (13 center dot 7% vs. 3 center dot 8% respectively;P = 0 center dot 18). Bacteria are the most frequent infections with ibrutinib, while viruses are most frequently involved with idelalisib.